Kineta (KA) News Today → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free KA Stock Alerts $0.53 +0.01 (+1.87%) (As of 01:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 18, 2024 | msn.comKineta (KA) Price Target Increased by 25.58% to 13.77April 9, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialApril 8, 2024 | globenewswire.comKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialMarch 22, 2024 | finanznachrichten.deKineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 21, 2024 | globenewswire.comKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedMarch 1, 2024 | bizjournals.comKineta CEO laid off as cutbacks leave biotech with 4 employeesFebruary 29, 2024 | msn.comKineta stock falls ~25.7% after co cuts workforce by 64%, including CEOFebruary 29, 2024 | globenewswire.comKineta Announces Restructuring and Exploration of Strategic AlternativesFebruary 22, 2024 | finance.yahoo.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 22, 2024 | globenewswire.comKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumFebruary 14, 2024 | finance.yahoo.comKineta to Present at Upcoming Investor ConferencesFebruary 14, 2024 | globenewswire.comKineta to Present at Upcoming Investor ConferencesFebruary 7, 2024 | stockhouse.comKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesJanuary 29, 2024 | finance.yahoo.comKA: Phase I/II UpdateJanuary 17, 2024 | finanznachrichten.deKineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsDecember 13, 2023 | finance.yahoo.comKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerDecember 12, 2023 | finance.yahoo.comKineta to Present at the Life Sciences Investor Forum December 14thNovember 28, 2023 | finance.yahoo.comKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023November 9, 2023 | finance.yahoo.comKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitNovember 8, 2023 | markets.businessinsider.comBuy Rating for Kineta Backed by Promising Drug Trials and Solid Financial PerformanceNovember 7, 2023 | msn.comKA: Third Quarter Results - MSNNovember 7, 2023 | finance.yahoo.comKA: Third Quarter ResultsNovember 6, 2023 | benzinga.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 4, 2023 | finance.yahoo.comKineta Insider Purchases Yet To Pay Off Regardless Of Recent StrengthNovember 4, 2023 | finanznachrichten.deKineta, Inc.: Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 3, 2023 | benzinga.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 3, 2023 | chron.comKineta: Q3 Earnings SnapshotNovember 3, 2023 | finance.yahoo.comKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNovember 3, 2023 | finance.yahoo.comKineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 18, 2023 | markets.businessinsider.comPromising Prospects for Kineta’s VISTA-101 Trial and KVA12123 Monotherapy Drive Buy RatingOctober 17, 2023 | finance.yahoo.comKineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsOctober 12, 2023 | finance.yahoo.comKA: Autumn ActivityOctober 12, 2023 | finance.yahoo.comKineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023October 12, 2023 | marketbeat.comTrading was temporarily halted for "KA" at 10:10 AM with a stated reason of "LULD pause."October 9, 2023 | finance.yahoo.comKineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023October 5, 2023 | finance.yahoo.comKineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesOctober 4, 2023 | finance.yahoo.comKineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesOctober 4, 2023 | finance.yahoo.comKineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 28, 2023 | finance.yahoo.comKineta Announces Participation at October Investor ConferencesSeptember 25, 2023 | finance.yahoo.comKineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 18, 2023 | finance.yahoo.comKineta Announces New Research Agreement to Evaluate VISTA Biomarker ExpressionSeptember 16, 2023 | finance.yahoo.comInsider Buying: Thierry Guillaudeux Acquires 10,000 Shares of Kineta IncAugust 31, 2023 | finance.yahoo.comKineta to Participate in Upcoming Investor ConferencesAugust 16, 2023 | finance.yahoo.comKA: Second Quarter ResultsAugust 15, 2023 | finance.yahoo.comKineta Second Quarter 2023 Earnings: Beats ExpectationsAugust 12, 2023 | finanznachrichten.deKineta, Inc.: Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | sfgate.comKineta: Q2 Earnings SnapshotAugust 11, 2023 | finance.yahoo.comKineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit KA Media Mentions By Week KA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KA News Sentiment▼0.430.56▲Average Medical News Sentiment KA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KA Articles This Week▼21▲KA Articles Average Week Get Kineta News Delivered to You Automatically Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lixte Biotechnology News Today Adial Pharmaceuticals News Today Enveric Biosciences News Today Lipella Pharmaceuticals News Today Hoth Therapeutics News Today First Wave BioPharma News Today Xenetic Biosciences News Today Processa Pharmaceuticals News Today Genprex News Today Sonnet BioTherapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldBill Clinton Backing Biden Replacement???The Freeport SocietyTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kineta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.